Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Mar 20
15-12B
Securities registration termination
19 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
POS AM
Prospectus update (post-effective amendment)
18 Mar 20
10-K
2019 FY
Annual report
12 Mar 20
8-K
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended Research and Development Expenses
12 Mar 20
8-K
Entry into a Material Definitive Agreement
10 Mar 20
25-NSE
Exchange delisting
9 Mar 20
425
Business combination disclosure
3 Mar 20
425
Business combination disclosure
28 Feb 20
8-K
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
6 Feb 20
425
Business combination disclosure
6 Feb 20
425
Business combination disclosure
6 Feb 20
425
Business combination disclosure
31 Jan 20
425
Business combination disclosure
28 Jan 20
DEFA14A
Additional proxy soliciting materials
28 Jan 20
425
Business combination disclosure
17 Jan 20
425
Business combination disclosure
16 Jan 20
425
Business combination disclosure
16 Jan 20
425
Business combination disclosure
15 Jan 20
8-K
AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne
14 Jan 20
425
Business combination disclosure
10 Jan 20
DEFA14A
Additional proxy soliciting materials
10 Jan 20
8-K
Foamix Announces AMZEEQTM(minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
9 Jan 20
DEFM14A
Proxy related to merger
7 Jan 20
425
Business combination disclosure
20 Dec 19
425
Business combination disclosure
20 Dec 19
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
18 Dec 19
425
Business combination disclosure
16 Dec 19
8-K
Other Events
16 Dec 19
425
Business combination disclosure
16 Dec 19
425
Business combination disclosure
9 Dec 19
8-K
Entry into a Material Definitive Agreement
4 Dec 19
425
Business combination disclosure
4 Dec 19
425
Business combination disclosure
4 Dec 19
425
Business combination disclosure
21 Nov 19
425
Business combination disclosure
14 Nov 19
Latest ownership filings
4
STANLEY STERN
18 Mar 20
4
Matthew T. Wiley
11 Mar 20
4
Iain Stuart
11 Mar 20
4
Aharon Schwartz
11 Mar 20
4
ANNA KAZANCHYAN
11 Mar 20
4
Stanley Hirsch
11 Mar 20
4
Mutya Harsch
11 Mar 20
4
Ilan Hadar
11 Mar 20
4
David Domzalski
11 Mar 20
4
Anthony D Bruno
11 Mar 20
4
Rex Bright
11 Mar 20
4
SHARON SURREY BARBARI
11 Mar 20
4
Matthew T. Wiley
3 Mar 20
4
Mutya Harsch
3 Mar 20
4
David Domzalski
3 Mar 20
4
STANLEY STERN
3 Mar 20
4
Aharon Schwartz
3 Mar 20
4
ANNA KAZANCHYAN
3 Mar 20
4
Stanley Hirsch
3 Mar 20
4
Anthony D Bruno
3 Mar 20
4
Rex Bright
3 Mar 20
4
Matthew T. Wiley
24 Feb 20
4
Iain Stuart
24 Feb 20
4
Mutya Harsch
24 Feb 20
4
Ilan Hadar
24 Feb 20
4
David Domzalski
24 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Foamix Pharmaceuticals Ltd.
14 Jan 20
4
Matthew T. Wiley
3 Jan 20
4
Iain Stuart
3 Jan 20
4
Mutya Harsch
3 Jan 20
4
David Domzalski
3 Jan 20
4
David Domzalski
3 Dec 19
4
Matthew T. Wiley
3 Dec 19
4
Mutya Harsch
3 Dec 19
4
Stanley Hirsch
5 Nov 19
4
Stanley Hirsch
17 Oct 19
4
Iain Stuart
2 Oct 19